Management of Alzheimer’s disease in the next ten years

Since the inception of clinical neuroscience, scientific breakthroughs have enhanced our knowledge of how certain pathologies impair the function of the nervous system. Alzheimer’s disease (AD) is a perpetual challenge in modern clinical neuroscience due to the ageing population, which makes individuals increasingly susceptible to AD. On a global scale, AD is the most common form of dementia and the number of people living with dementia worldwide has more than doubled from 1990 to 2016, which warrants prompt development of effective interventions that may halt or delay disease progression. This narrative review recommends further investigation into the effectiveness of monoclonal antibody treatment in patients with early AD and the utilisation of several laboratory tools to understand the complex aetiology of AD. In the next ten years, it is hoped that the recommendations in this article may come to fruition and facilitate further advancements in clinical neuroscience to develop therapies that delay the onset and even reverse the clinical manifestation of AD that currently has a poor prognosis.